Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

OHSU studying drug for bone-deforming disorder

22.05.2006


Researchers seek therapy for osteogenesis imperfecta, which can lead to hundreds of fractures in a lifetime



Jimmy Fox isn’t typical of a person with the genetic, "brittle bone" disorder osteogenesis imperfecta (OI). He lifts weights almost daily, participates in grueling wheelchair races, chops wood and enjoys hunting in rough backcountry.

Still, Fox, who owns a busy combination grocery store-gun shop in Cloverdale, Ore., is eager to participate in an Oregon Health & Science University-led study of a drug that may help reduce the debilitating effects of OI, an inherited disorder characterized by weak bones that break easily. People with the most severe forms of OI have short stature, can suffer hundreds if not thousands of fractures in a lifetime, and are confined to a wheelchair.


"I didn’t think it could do me any harm," Fox, 40, said of the study. He has a less-severe form of OI, allowing him to be more mobile - he walks on his hands when he’s not in his wheelchair - and suffer fewer fractures than many others with the disorder. Fox had both of his legs amputated when he was 18 due to continued fracturing. "The study might do me some good, so I thought I might as well do it and give it a try. It will help other people."

The alternative is unacceptable to Fox, who acknowledges that his significant upper-body strength has kept many of the disorder’s most debilitating effects at bay. "They told me ’If you weren’t as active as you are, you would be totally screwed up by now.’ To be honest, that’s what really swayed me to do this."

The study, headed by Eric Orwoll, M.D., professor of medicine (endocrinology, diabetes and clinical nutrition) and director of the Bone and Mineral Unit, OHSU School of Medicine, is examining the effectiveness of the synthesized parathyroid hormone, teriparatide, in increasing bone mass and improving bone structure in adults affected by OI. Teriparatide, derived from the human parathyroid gland, is manufactured and sold by Eli Lilly and Co. under the brand name FORTEO.

FORTEO already is approved for use by men and postmenopausal women with osteoporosis who are at high risk for having fractures, according to Lilly’s Web site.

"It gives a lot of hope to a lot of people who wouldn’t have much to look forward to," Orwoll said.

In most OI patients, the disorder is caused by a mutation in one of two genes, COL1A1 and COL1A2, that encode for type 1 collagen, the fibrous protein that serves as the scaffolding for bone and which also is present in ligaments, tendons, teeth, the white portion of the eyes, and even skin. The defect impairs the body’s ability to mineralize bone and other collagen-containing tissue, leading to bone fragility, loose joints, eye discoloration, dental problems and premature hearing loss.

Although exact incidence isn’t known, OI is believed to affect 1 of every 5,000 to 10,000 individuals of all racial and ethnic origins, with between 20,000 and 50,000 Americans living with the disorder. Parents with OI have a 50 percent chance with each pregnancy of having an affected child and most children with the disorder have inherited it from a parent. About a fourth of all children with OI are born into families with no history of the disorder.

Janet Reeder, M.S., PA-C, a former faculty member of the OHSU Bone and Mineral Unit who developed the study, said people with OI are largely ignored by the medical community because few treatment options exist, or doctors fear treatment will cause more fractures.

"Many practitioners say, ’We don’t know what to do with you. Sorry, have a nice life,’" Reeder said. "But they pay taxes, they work full time. They have incredible tenacity. This is a group of people that has really triumphed over a lot of disability and deformity. What we’re trying to do is help them by hopefully decreasing fractures and thereby increasing quality of life."

There is no cure for the disorder, and while drugs have been studied for use in children with OI, there is no established medical therapy for affected adults. Adult OI treatment varies depending on the degree of impairment and the patient’s age. Doctors sometimes surgically implant rods to support long bones or prescribe braces to support lower limbs. Patients also are encouraged to take calcium and vitamin D supplements daily.

"What we’re interested in is, after kids make it through childhood and into adulthood, what can we do for them?" Orwoll said.

Each of the three national study sites - OHSU, Kennedy Krieger Institute at Johns Hopkins University, and Baylor School of Medicine - are recruiting a total of 90 men and women ages 18 and older for the 18-month, blinded trial. Participants will receive either FORTEO or a placebo, which is self-administered once a day using an injection pen. They will be examined at the first, third, sixth, 12th and 18th months after initial screening, and their spine, hip, forearm and total body bone mineral density will be measured every six months.

FORTEO offers hope of suffering fewer bone fractures for individuals with OI such as Anton Borissov, a 40-year-old Portland resident who has never walked and lives in his wheelchair. It also will increase awareness about the disorder, which may lead to even more drug therapies.

"For me, it is a big, big thing not to have breaks. When I lift something it’s just ’break, break, break,’" said Borissov, a native of Russia who estimates he’s suffered a thousand fractures in his lifetime, and who can break ribs just by coughing. He is not a participant in the FORTEO study. "If they’re doing this study, it’s good. And people will know something about OI, even doctors, and that I’m no different."

Jonathan Modie | EurekAlert!
Further information:
http://www.ohsu.edu

More articles from Health and Medicine:

nachricht Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Foods of the future
15.08.2018 | Georg-August-Universität Göttingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

Im Focus: Lining up surprising behaviors of superconductor with one of the world's strongest magnets

Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur

What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

2018 Work Research Conference

25.07.2018 | Event News

 
Latest News

Staying in Shape

16.08.2018 | Life Sciences

Diving robots find Antarctic seas exhale surprising amounts of carbon dioxide in winter

16.08.2018 | Earth Sciences

Protein droplets keep neurons at the ready and immune system in balance

16.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>